天风证券给予凯立新材买入评级

Group 1 - The core viewpoint of the report is that despite a decline in quarterly revenue, the company's profit has increased on a month-on-month basis, and the gross profit margin has reached a three-year high [2] - The pharmaceutical and basic chemical sales have experienced rapid growth, and high-priced sales have driven revenue growth in the first half of the year [2] - The company has made significant progress in catalyst research and development, with breakthroughs in basic chemical projects and the HNBR entering trial operation [2]